Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Chronic obstructive pulmonary disease, bronchial asthma and allergic rhinitis in the adult population within the commonwealth of independent states: rationale and design of the CORE study.

Feshchenko Y, Iashyna L, Nugmanova D, Gyrina O, Polyanskaya M, Markov A, Moibenko M, Makarova J, Tariq L, Pereira MHS, Mammadbayov E, Akhundova I, Vasylyev A.

BMC Pulm Med. 2017 Oct 10;17(1):131. doi: 10.1186/s12890-017-0471-x.

2.

Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Ukraine.

Feshchenko Y, Dzyublik A, Pertseva T, Bratus E, Dzyublik Y, Gladka G, Morrissey I, Torumkuney D.

J Antimicrob Chemother. 2016 May;71 Suppl 1:i63-9. doi: 10.1093/jac/dkw068.

3.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators.

N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777.

4.

Tiotropium Respimat inhaler and the risk of death in COPD.

Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators.

N Engl J Med. 2013 Oct 17;369(16):1491-501. doi: 10.1056/NEJMoa1303342. Epub 2013 Aug 30.

5.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
6.

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.

Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C; P04073 Study Investigators.

Eur Respir J. 2012 Feb;39(2):279-89. doi: 10.1183/09031936.00020310. Epub 2011 Aug 4.

7.

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators.

N Engl J Med. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378.

8.

Fondaparinux for the treatment of superficial-vein thrombosis in the legs.

Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A; CALISTO Study Group.

N Engl J Med. 2010 Sep 23;363(13):1222-32. doi: 10.1056/NEJMoa0912072.

9.

Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.

Weinstein SF, Corren J, Murphy K, Nolte H, White M; Study Investigators of P04431.

Allergy Asthma Proc. 2010 Jul-Aug;31(4):280-9. doi: 10.2500/aap.2010.31.3381. Epub 2010 Aug 3.

PMID:
20687982
10.

Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.

Nathan RA, Nolte H, Pearlman DS; P04334 Study Investigators.

Allergy Asthma Proc. 2010 Jul-Aug;31(4):269-79. doi: 10.2500/aap.2010.31.3364. Epub 2010 Jul 30.

PMID:
20678306

Supplemental Content

Loading ...
Support Center